Internal and Emergency Medicine

, Volume 13, Issue 3, pp 313–318 | Cite as

Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist

  • Domenico GirelliEmail author
  • Fabiana Busti
  • Giacomo Marchi
  • Nicola Martinelli
  • Oliviero Olivieri


The idea of using small RNA fragments (oligonucleotides) for therapeutic purposes dates back to the 1990s, following the landmark discoveries on the mechanisms of gene silencing and RNA-interference (RNA-i). However, the first applications in medicine were hampered by difficulties in chemical stabilization and efficient delivery to target tissues. Recent advances in chemical manipulation of oligonucleotides have, at least partially, bypassed such obstacles. In particular, conjugation with ligands for specific receptors allows the selective uptake of oligonucleotides by critical cells (e.g., hepatocytes), where they inhibit the synthesis of the target protein by binding the complementary mRNA and inducing its degradation. In parallel, next-generation sequencing (NGS) studies at population levels have identified a number of key molecular targets, mainly through the discovery of “human knock-outs,” i.e., subjects lacking a given protein because of nonsense mutations in the corresponding gene. Such highly informative individuals are often healthy, or even protected from the development of certain diseases. Indeed, subjects with null mutations in certain genes controlling lipoprotein metabolism like PCSK9 or ANGPTL-3 have a lower risk of cardiovascular disease. Since the complete absence of such proteins does not appear to carry any negative health effect, the corresponding genes are ideal candidates for the silencing approach. Pilot clinical trials with long acting anti-PCSK9 or anti-ANGPTL-3 oligonucleotides have yielded very promising results, so that their use as “vaccines” against atherosclerosis has been suggested in the future. As therapeutic oligonucleotides can virtually target innumerable proteins, their increasing development is predicted to substantially expand the repertoire of the “biological drugs,” in addition to, or even substituting, more consolidated approaches like monoclonal antibodies.


Antisense oligonucleotides Gene silencing Cardiovascular diseases 



DG, OO, and NM are recipients of research grants from the Cariverona Foundation. Funding was provided by Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona (IT) (Grant no. 2015.0872) and Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona (Grant no. 2014.0851).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent



  1. 1.
    Girelli D, Piubelli C, Martinelli N, Corrocher R, Olivieri O (2017) A decade of progress on the genetic basis of coronary artery disease. Practical insights for the internist. Eur J Intern Med 41:10–17CrossRefPubMedGoogle Scholar
  2. 2.
    Bennett CF, Baker BF, Pham N, Swayze E, Geary RS (2017) Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol 57:81–105CrossRefPubMedGoogle Scholar
  3. 3.
    Khvorova A, Watts JK (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35:238–248CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Khvorova A (2017) Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med 376:4–7CrossRefPubMedGoogle Scholar
  5. 5.
  6. 6.
    Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q et al (2014) Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 136:16958–16961CrossRefPubMedGoogle Scholar
  7. 7.
    Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V et al (2017) A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376:41–51CrossRefPubMedGoogle Scholar
  8. 8.
    Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ (2014) Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 13:828–851CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Holderfield M (2017) Efforts to develop KRAS inhibitors. Cold Spring Harb Perspect Med. PubMedGoogle Scholar
  10. 10.
    Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N et al (2017) Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Sci Transl Med 9(394).
  11. 11.
    Girelli D, Martinelli N, Peyvandi F, Olivieri O (2009) Genetic architecture of coronary artery disease in the genome-wide era: implications for the emerging “golden dozen” loci. Semin Thromb Hemost 35:671–682CrossRefPubMedGoogle Scholar
  12. 12.
    Stitziel NO, Kathiresan S (2017) Leveraging human genetics to guide drug target discovery. Trends Cardiovasc Med 27:352–359CrossRefPubMedGoogle Scholar
  13. 13.
    Kaiser J (2014) The hunt for missing genes. Science 344:687–689CrossRefPubMedGoogle Scholar
  14. 14.
    Saleheen D, Natarajan P, Armean IM, Zhao W, Rasheed A, Khetarpal SA et al (2017) Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature 544:235–239CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE et al (2017) ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol 69:2054–2063CrossRefPubMedGoogle Scholar
  16. 16.
    Plenge RM (2017) Biomedicine: human genes lost and their functions found. Nature 544:171–172CrossRefPubMedGoogle Scholar
  17. 17.
    Khera AV, Kathiresan S (2017) Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet 18:331–344CrossRefPubMedGoogle Scholar
  18. 18.
    Monteleone G, Pallone F (2015) Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med 372:2461CrossRefPubMedGoogle Scholar
  19. 19.
    Messina S, Pane M, Sansone V, Bruno C, Catteruccia M, Vita G et al (2017) Expanded access program with Nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience. Neuromuscul Disord 27:1084–1086CrossRefPubMedGoogle Scholar
  20. 20.
    Nelson SF, Miceli MC (2017) FDA approval of eteplirsen for muscular dystrophy. JAMA J Am Med Assoc 317:1480CrossRefGoogle Scholar
  21. 21.
    Goemans N, Mercuri E, Belousova E, Komaki H, Dubrovsky A, McDonald CM et al (2018) A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscul Disord 28:4–15CrossRefPubMedGoogle Scholar
  22. 22.
    Buller HR, Gailani D, Weitz JI (2015) Factor XI antisense oligonucleotide for venous thrombosis. N Engl J Med 372:1672CrossRefPubMedGoogle Scholar
  23. 23.
    Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239–2253CrossRefPubMedGoogle Scholar
  24. 24.
    Tsimikas S (2017) A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 69:692–711CrossRefPubMedGoogle Scholar
  25. 25.
    Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W et al (2015) Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 373:438–447CrossRefPubMedGoogle Scholar
  26. 26.
    Geary RS, Baker BF, Crooke ST (2015) Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro((R))): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet 54:133–146CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH et al (2012) Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 33:1142–1149CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Natarajan P, Kathiresan S (2016) PCSK9 inhibitors. Cell 165:1037CrossRefPubMedGoogle Scholar
  29. 29.
    Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M et al (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 376:1430–1440CrossRefPubMedGoogle Scholar
  30. 30.
    Ummarino D (2017) Dyslipidaemia: anti-PCSK9 vaccines to halt atherosclerosis. Nat Rev Cardiol 14:442–443CrossRefPubMedGoogle Scholar

Copyright information

© SIMI 2018

Authors and Affiliations

  1. 1.Section of Internal Medicine, Department of MedicineUniversity of Verona and Azienda Ospedaliera Universitaria Integrata of VeronaVeronaItaly

Personalised recommendations